i
Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection
-
Feb 2018
Source: Emerg Infect Dis. 24(2):328-335.
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.
-
Subject:
-
Source:
-
Pubmed ID:29350154
-
Pubmed Central ID:PMC5782881
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
gif jpeg gif jpeg xml
More +